Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Cobolimab
Price:
Purity: 95.0%
Stocking Period: 10 Day
Contact: Yang

2022215-65-0

2022215-65-0 structure

2022215-65-0 structure

Name: Cobolimab
Chemical Name: Cobolimab
CAS Number: 2022215-65-0
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-05-07 21:22:45
Modify Date: 2024-04-08 17:23:55
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].

Name	Cobolimab

Description	Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].
Related Catalog	Research Areas >> Cancer
In Vitro	Cobolimab (0.0001-10 nM；3 d) 在预激活 T 细胞中以剂量依赖性方式促进 TIM-3 内化，IC50 值为 0.4464 nM[3]。 Cobolimab (20 µg/mL；24 h) 通过抑制 TIM-3 显著增加了 CD8+ T 细胞含量[4]。
References	[1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.

No Any Chemical & Physical Properties